Effect of metformin on lung function in diabetic or prediabetic individuals with respiratory disease

Phase 2

Completed

• Conditions: Chronic obstructive pulmonary disease; Type 2 diabetes mellitus; Impaired glucose tolerance; Insulin resistance; Respiratory - Chronic obstructive pulmonary disease; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12610000378022
• Lead Sponsor: Dr Paul Sexton

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

*Obese (body mass index > 30)
*Central pattern of obesity (elevated waist circumference)
*Impaired glucose tolerance or diet-controlled type 2 diabetes mellitus (previous diagnosis, or evidence of blood tests meeting American Diabetes Association 2010 criteria)
*Post-bronchodilator spirometry that is consistent with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2+ COPD
*Symptomatic: Medical Research Council dyspnoea score of 2 or higher

Exclusion Criteria

1.Currently taking oral hypoglycaemic agent or insulin
2.Active respiratory disease other than obstructive airways disease
3.Exacerbation of airways disease requiring change in treatment within the preceding 6 weeks
4.Participation in pulmonary rehabilitation programme within the past 6 weeks
5.Currently prescribed long term oral corticosteroids
6.Renal impairment (estimated glomerular filtration rate < 45 mL/min)
7.Cirrhosis, impaired synthetic liver function, or liver failure
8.Chronic respiratory failure
9.Congestive heart failure
10.Current or recent habitual heavy alcohol intake
11.Current use of antiretroviral medication
12.Pregnancy
13.History of lactic acidosis
14.Allergy to metformin
15.Unable to comply with the study procedures or protocol

Study & Design

• Study Type: Interventional
• Study Design: Not specified